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Herpes Simplex -
A New Approach 
Herpes viruses cause a wide spectrum of clinical 
conditions ranging from the cold sore to herpes 
enchephalitis. They are characterised by their ability 
to take up permanent residence in the host, in a latent 
or quiescent state. Under certain circumstances the 
virus, which probably resides in the nerve ganglia, is 
reactivated and causes a recurrence of the clinical 
manifestations of infection 
Unlike bacteria, viruses are not free living 
organisms and are dependent upon the life processes 
of the cell to replicate. This close association between 
virus and' cell inevitably resulted in antiviral agents 
causing unwanted effects on host cells, such as bone 
marrow suppression, teratogenicity and many other 
effects; thus confining the use ofthese agents to short-
term topical application. 
Wellcome's new product Acyclovir, previously 
known as acyuco 19uanosine~, is the first selective 
antiviral agent. The drug is active against the virus 
without exerting an e.ffect upon the host cell by virtue 
of a two stage mechanism of action. 
1. Selective concentration in infected cells. 
This is the result of a) its conversion to the active 
form acyclovir tri-phosphate by a herpes virus 
enzyme - thymidine kinase. b) The active drug is 
not able to diffuse out of the cell and thus 
maintains an acyclovir concentration gradient 
within the cell. Host cell enzymes are unable to 
carry out this conversion to any significant 
extent, and so little or no active drug is formed in 
normal cells. 
2. Inhibition of herpes DNA synthesis. 
Deoxyguanosine tri-phosphate is incorporated 
into viral DNA and is a vital constituent for viral 
replication. Acyclovir tri-phosphate competes 
with deoxyguanosine tri-phosphate as a DNA 
polymerase substrate, but it cannot be 
incorporated into D~A in a way that will allow 
replication. Thus viral replication is inhibited. 
Since acyclovir is activated only when the herpes 
simplex virus is present, it seals its own fate and 
normal cells are left unharmed. In fact it takes 3000 
times more drug to affect normal cells than it does to 
inhibit the virus. 
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Whilst the ointment represents a significant 
advance in its particular area of use, the major impact 
of the drug is likely to be in other areas. By virtue of its 
lack of toxicity acyclovir may well be the first drug to 
enjoy widespread systemic use for treating herpes 
infections, although further work is needed. With 
intravenous acyclovir use transient renal impairment 
is seen as rises in plasma urea and serum creatinine 
levels. Acyclovir is relitively insoluble and largely 
excreted by the kidney, and it is possible that it is a 
recrystallization of the drug in the renal tubules which 
causes this effect. Care is therefore required in 
patients who are dehydrated or who have underlying 
renal disease, although no permanent kidney 
dysfunction has been seen. The results suggest that a 
more appropriate form of systemic therapy; such as 
oral or intramuscular administration, will provide 
significant benefit to patients suffering from herpes 
zoster infections. 
Because of its low toxicity and high efficacy the 
results of early clinical trials have been received with 
enthusiasm. 
"Acyclovir was found to be between 5 and 10 times 
active than cytarabine, ido uridine land 
trifiuorothymidine, and more than 100 times more 
active than vidarabine." 
(J. Antimicrob. Chemother., (1979), 5, 431) 
"The present paper reports the selectivity of action of 
a new class of antiviral agent that has extremely low 
toxicity for normal cells while having an inhibitory 
activity agianst HSV which is greater than that of any 
hithero known compound." 
(proc. Natl. Acad. Sci. USA., (1977), 74/12, 5716) 
"No adverse effects were seen with the 
acycloguanosine therapy." 
(Jones, Bet al Lancet, (1979), 1, 243) 
Condensed from an article in the Postgraduate Medical Digest No. 
8 December 1981. Acyclovir lis marketed by the Wellcome 
Foundation Ltd. under the name of Zovirax. 
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